Products & Programs PharmacyCommercialFebruary 28, 2022

Clinical Criteria updates for specialty pharmacy

Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem.

Material Adverse Change (MAC)


Empire BlueCross BlueShield’s pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by Empire’s medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health (AIM), a separate company.

 

The following clinical criteria documents were endorsed at the December 13, 2021 Clinical Criteria meeting. To access the clinical criteria information please click here.

 

Archived clinical criteria effective December 30, 2021

The following clinical criteria document has been archived.

  • ING-CC-0181 Veklury (remdesivir)

 

New clinical criteria effective January 4, 2022

The following clinical criteria are new.

  • ING-CC-0205 Fyarro (sirolimus albumin bound)
  • ING-CC-0206 BESREMi (ropeginterferon alfa-2b-njft)

 

New clinical criteria effective January 17, 2022

The following clinical criteria are new.

  • ING-CC-0207 Vyvgart (efgartigimod alfa-fcab)
  • ING-CC-0208 Adbry (tralokinumab)
  • ING-CC-0209 Leqvio (inclisiran)

 

Revised clinical criteria effective January 28, 2022

The following clinical criteria was revised to expand medical necessity indications or criteria.

  • ING-CC-0072 Selective Vascular Endothelial Growth Factor (VEGF) Antagonists

 

Revised clinical criteria effective January 31, 2022

The following clinical criteria were revised to expand medical necessity indications or criteria.

  • ING-CC-0015 Infertility and HCG Agents
  • ING-CC-0029 Dupixent (dupilumab)
  • ING-CC-0079 Strensiq (asfotase alfa)
  • ING-CC-0124 Keytruda (pembrolizumab)
  • ING-CC-0168 Tecartus (brexucabtagene autoleucel)

 

Revised clinical criteria effective January 31, 2022

The following clinical criteria were reviewed with no significant change to the medical necessity indications or criteria.

  • ING-CC-0018 Agents for Pompe Disease
  • ING-CC-0154 Givlaari (givosiran)
  • ING-CC-0185 Oxlumo (lumasiran)
  • ING-CC-0190 Nulibry (fosdenopterin)
  • ING-CC-0198 Relizorb (immobilized lipase) cartridge

 

Revised clinical criteria effective June 1, 2022

The following clinical criteria was revised and might result in services that were previously covered but may now be found to be not medically necessary.

  • ING-CC-0004 Repository Corticotropin Injection

 

632-0322-PN-NY

PUBLICATIONS: March 2022 Newsletter